What is Phase II Masitinib Study?

Category: Others


The Phase II Masitinib Study is a prospective, multicenter, randomized, double-blind, placebo-controlled study to compare the efficacy and safety of masitinib versus placebo in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS). The EudraCT number is 2010-024423-24.

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations
Severe 0
Moderate 0
Mild 0
None 1

Commonly reported side effects and conditions associated with Phase II Masitinib Study

Side effect Patients
Adherence Evaluations
Always 1
Usually 0
Sometimes 0
Never taken as prescribed 0
Burden Evaluations
Very hard to take 0
Somewhat hard to take 0
A little hard to take 0
Not at all hard to take 1
Last updated:
There are no evaluations for Phase II Masitinib Study.